Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program ...
Personalis Inc. PSNL received a favorable reimbursement decision that could make its cancer test available to more patients — ...
Coverage marks a pivotal step in expanding access to ultra-sensitive MRD detection for breast cancer patients U.S. Medicare coverage decision reflects published, peer-reviewed clinical data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results